Bromocriptine in type 2 diabetes mellitus

Bromocriptine mesylate quick-release was approved by the Food and Drug Administration (FDA) in May 2009, for the treatment of type 2 diabetes. Bromocriptine is thought to act on the circadian neuronal activities in the hypothalamus, to reset an abnormally elevated hypothalamic drive for increased pl...

Full description

Bibliographic Details
Main Authors: C Shivaprasad, Sanjay Kalra
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2011-01-01
Series:Indian Journal of Endocrinology and Metabolism
Subjects:
Online Access:http://www.ijem.in/article.asp?issn=2230-8210;year=2011;volume=15;issue=5;spage=17;epage=24;aulast=Shivaprasad
_version_ 1819030605282672640
author C Shivaprasad
Sanjay Kalra
author_facet C Shivaprasad
Sanjay Kalra
author_sort C Shivaprasad
collection DOAJ
description Bromocriptine mesylate quick-release was approved by the Food and Drug Administration (FDA) in May 2009, for the treatment of type 2 diabetes. Bromocriptine is thought to act on the circadian neuronal activities in the hypothalamus, to reset an abnormally elevated hypothalamic drive for increased plasma glucose, free fatty acids, and triglycerides in insulin-resistant patients. Randomized controlled trials have shown that bromocriptine-QR lowers glycated hemoglobin by 0.4 - 0.8% either as monotherapy or in combination with other anti-diabetes medications. The doses used to treat diabetes (up to 4.8 mg daily) are much lower than those used to treat Parkinson′s disease, and apart from nausea, the drug is well-tolerated. The novel mechanism of action, good side effect profile, and its effects to reduce cardiovascular event rates make it an attractive option for the treatment of type 2 diabetes.
first_indexed 2024-12-21T06:32:48Z
format Article
id doaj.art-5d53d4435cb341d3ac7f552ab9349412
institution Directory Open Access Journal
issn 2230-8210
2230-9500
language English
last_indexed 2024-12-21T06:32:48Z
publishDate 2011-01-01
publisher Wolters Kluwer Medknow Publications
record_format Article
series Indian Journal of Endocrinology and Metabolism
spelling doaj.art-5d53d4435cb341d3ac7f552ab93494122022-12-21T19:12:57ZengWolters Kluwer Medknow PublicationsIndian Journal of Endocrinology and Metabolism2230-82102230-95002011-01-01155172410.4103/2230-8210.83058Bromocriptine in type 2 diabetes mellitusC ShivaprasadSanjay KalraBromocriptine mesylate quick-release was approved by the Food and Drug Administration (FDA) in May 2009, for the treatment of type 2 diabetes. Bromocriptine is thought to act on the circadian neuronal activities in the hypothalamus, to reset an abnormally elevated hypothalamic drive for increased plasma glucose, free fatty acids, and triglycerides in insulin-resistant patients. Randomized controlled trials have shown that bromocriptine-QR lowers glycated hemoglobin by 0.4 - 0.8% either as monotherapy or in combination with other anti-diabetes medications. The doses used to treat diabetes (up to 4.8 mg daily) are much lower than those used to treat Parkinson′s disease, and apart from nausea, the drug is well-tolerated. The novel mechanism of action, good side effect profile, and its effects to reduce cardiovascular event rates make it an attractive option for the treatment of type 2 diabetes.http://www.ijem.in/article.asp?issn=2230-8210;year=2011;volume=15;issue=5;spage=17;epage=24;aulast=ShivaprasadBromocriptinecircadian rhythmdiabetesinsulin resistancequick release formulation
spellingShingle C Shivaprasad
Sanjay Kalra
Bromocriptine in type 2 diabetes mellitus
Indian Journal of Endocrinology and Metabolism
Bromocriptine
circadian rhythm
diabetes
insulin resistance
quick release formulation
title Bromocriptine in type 2 diabetes mellitus
title_full Bromocriptine in type 2 diabetes mellitus
title_fullStr Bromocriptine in type 2 diabetes mellitus
title_full_unstemmed Bromocriptine in type 2 diabetes mellitus
title_short Bromocriptine in type 2 diabetes mellitus
title_sort bromocriptine in type 2 diabetes mellitus
topic Bromocriptine
circadian rhythm
diabetes
insulin resistance
quick release formulation
url http://www.ijem.in/article.asp?issn=2230-8210;year=2011;volume=15;issue=5;spage=17;epage=24;aulast=Shivaprasad
work_keys_str_mv AT cshivaprasad bromocriptineintype2diabetesmellitus
AT sanjaykalra bromocriptineintype2diabetesmellitus